Wohua Pharmaceutical released its 2026 interim report, with net profit attributable to the parent company at 67.5663 million yuan, up 51.23% from the same period last year, marking two consecutive years of growth. The company's total operating revenue was 393 million yuan, down 7.53% year-on-year. Net cash inflow from operating activities was 81.3675 million yuan, an increase of 8.07% year-on-year. The company's latest asset-liability ratio is 26.32%, gross margin is 77.84%, ROE is 9.56%, and diluted earnings per share is 0.12 yuan.
Shandong Wohua Pharmaceutical Co LtdNet profit attributable to parent rose 51.23% year-on-year, marking two consecutive years of growth.